Q BioMed Inc CEO Denis Corin, CEO and Mannin Research Inc CEO Dr George Nikopoulos joined Proactive's Stephen Gunnion with news that the companies are poised to start clinical trials of their MAN-19 therapeutic in 2022.
The MAN-19 therapeutic is a recombinant fusion protein and is being assessed to treat acute respiratory distress syndrome (ARDS), which is caused by viral infections in the lungs including coronavirus (COVID-19).